Autoimmune liver disease-related autoantibodies in patients with biliary atresia

Table 4 Prevalence of anti-neutrophil cytoplasmic antibodies in biliary atresia patients and non-biliary atresia controls n (%)

Variable	BA, n = 124	Other liver diseases1, n = 92	Healthy, n = 48
ANCA, by IIF	36 (29.0)a	23 (25.0)	2 (4.2)
c-ANCA	10 (8.1)	1 (1.1)	0 (0)
p-ANCA	25 (20.2)	21 (22.8)	2 (4.2)
a-ANCA	1 (0.8)	1 (1.1)	0 (0)
Specific ANCA, by ELISA
Anti-MPO	11 (8.9)	6 (6.5)	2 (4.2)
Anti-PR3	19 (15.3)	13 (14.2)	0 (0)
Anti-MPO and/or anti-PR3	23 (18.0)a	13 (14.2)	2 (4.2)
ANCAs	47 (37.9)a	31 (33.7)	3 (6.3)

¹Choledochal cysts, transient cholestasis of unknown origin, and neonatal intrahepatic cholestasis caused by citrin deficiency were included as disease controls.

^aP < 0.05 vs healthy controls. Anti-MPO and/or anti-PR3: Any positivity of specific ANCAs; ANCAs: Any positivity of ANCAs by IIF or specific ANCA by ELISA. ANCA: Anti-neutrophil cytoplasmic antibody; BA: Biliary atresia; ELISA: Enzyme linked immunosorbent assay; IIF: Indirect immunofluorescence.